Company intelligence / Profile preview

SonALAsense

Oakland, California, United Statessonalasense.com ↗

Ownership: Private
Development stage: Phase 2

Overview

SonALAsense has shown positive proof of concept in a Phase 0/1 clinical trial for recurrent high-grade gliomas (rHGG). Initial results indicate SDT rapidly leads to targeted cell death in human glioma tissue and was well-tolerated in all patients. The company has completed the first cohort in a Phase 2 study for recurrent glioblastoma and is actively recruiting for a DIPG trial.

Therapeutic areas: OncologyHematology
Modalities: Drug-device combination therapy
Industry: Biotech

Drug pipeline

1 asset

SONALA-001

Phase 2

Indications: Glioblastoma, Diffuse intrinsic pontine glioma, Blood cancers

Partnerships

Ivy Brain Tumor Center at Barrow Neurological InstituteEnd Brain Cancer Initiative

Beyond the preview

Go deeper on SonALAsense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SonALAsense.

Explore the full profile